In this proposal, we will investigate the therapeutic properties of recombinant fusion protein directed to tumor-associated antigen, IL13Rα2, via scFv47 attached to a mutated form of superantigen staphylococcal enterotoxin E (SEA/E-120) in murine glioma models of disease. The NeoTx will provide purified recombinant protein and corresponding negative control protein for analysis. The Northwestern University (PI: Irina Balyasnikova) will perform validations of the activity of the recombinant protein in murine models of glioblastoma in vitro and in vivo.
|Effective start/end date||12/1/20 → 2/28/23|
- Neotx Holdings Ltd. (Amendment #2)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.